

**FOOD AND DRUG ADMINISTRATION
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH**

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE

MEETING ON INFLUENZA VIRUS VACCINE FORMULATION FOR 2002-2003
AND CBER LABORATORY SITE VISIT FOR LHV AND LVBVD

MEETING BY TELECONFERENCE

AGENDA

WEDNESDAY, MARCH 6, 2002

BUILDING 29, ROOM 121

Bethesda, Maryland

12:30 PM EST

12:30 PM	Call to Order	Dr. Daum, Committee Chair
12:35	Announcements	Dr. Jody Sachs, FDA
12:40	Session 1- Open Session	
	Strain Selection for the Influenza Virus Vaccine for 2002-2003	
	Introduction and Review	Dr. Levandowski, FDA
	Additional Information, A H3N2 and B Viruses	Dr. Nancy Cox, CDC Dr. Levandowski, FDA
1:30	Committee Discussion	
2:00	Open Public Hearing for Session 1	
2:30	Recommendations for Influenza Virus Vaccine for 2002-2003	
2:45	Session 2- Open Session	
	Brief Overview of the CBER Laboratories that underwent Site Visit:	
	Overview of the Division of Viral Products	Dr. Jerry Weir
2:50	Synopsis of Laboratory of Hepatitis Virus (LHV)	Dr. Stephen Feinstone
3:05	Synopsis of Laboratory of Vector-borne Viral Diseases (LVVD)	Dr. Lewis Markoff
3:20	Open Public Hearing for Session 2	
3:50	Session 3- Closed Session	
	Site Visit Report Discussion and Committee Recommendations	
4:50	Adjournment	